FDA approves atezolizumab with chemotherapy after surgery for stage III dMMR colon cancer
On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
The CDC reported on a botulinum toxin product not approved by the FDA that was used at a Colorado medical spa.
On 8 October 2026 WHO and partners launched a global roadmap on hypertensive disorders of pregnancy.
On 7 October 2026 the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer.
On 7 October 2026 WHO released its first global guidelines on caring for children and adolescents with obesity.
An Aesthetic Surgery Journal study compared 1,036 face-and-neck-lift patients with or without tranexamic acid.
On 2 October 2026 the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia.
WHO’s latest Global Health Estimates put global life expectancy at 73.3 years in 2023, close to 73.4 in 2019.
An Aesthetic Surgery Journal article examines the ethics of surgeons analysing celebrities' looks on social media.
The FDA has published new information warning about clear aligners sold directly to consumers.
Nothing more to show